A behavioral Intervention improves the rate of hepatitis C treatment initiation among HIV/HCV coinfected patients: results of a randomized controlled trial by Weiss, J.J, Aaronson, C, Cervantes, L, Georgi, M, Prochno, K, Miller, T.R, Kang, T, Prieto, S, Mhango, G, Heffron, S, Lugo, L.A, Fishberger, J, Zewde, M, Stivala, A, Douglas, O, Ferris, D, Dieterich, D.T, Wisnivesky, J

Get full text

485 HEPATITIS OUTREACH NETWORK: A PRACTICAL STRATEGY FOR HEPATITIS SCREENING WITH LINKAGE TO CARE IN FOREIGN BORN COMMUNITIES by Perumalswami, P, Factor, S.H, Kapelusznik, L, Friedman, S.L, Pan, C.Q, DiClemente, F, Chang, C, Dieterich, D.T

Get full text

P0881 : Real world effectiveness and cost of simeprevir- and/or sofosbuvir-based HCV treatments: $175,000 per SVR12 by Bichoupan, K, Tandon, N, Del Bello, D, Patel, N, Yalamanchili, R, Chekuri, S, Harty, A, Chang, S, Ku, L, Ng, M, Motamed, D.B, Sigel, K.M, Gardenier, D, Stivala, A, Khaitova, V, Bansal, M.B, Grewal, P, Agarwal, R, Chang, C.Y, Leong, J, Im, G.Y, Liu, L.U, Odin, J.A, Bach, N, Friedman, S.L, Schiano, T.D, Perumalswami, P, Dieterich, D.T, Branch, A.D

Get full text

917 PROACTIVE BIRTH-COHORT AND RISK-BASED HEPATITIS C SCREENING: HEP C LINK TO CARE NYC by Gaglio, P.J, Petschow, B.W, Brown, R.S, Jacobson, I.M, Bernstein, D, Palmer, M, Perumalswami, P.V, Dieterich, D.T

Get full text

795 REAL WORLD COSTS OF TELAPREVIR-BASED TRIPLE THERAPY, INCLUDING COSTS OF MANAGING ADVERSE EVENTS, AT THE MOUNT SINAI MEDICAL CENTER, NY: $147,000 PER EOT by Bichoupan, K, Martel-Laferriere, V, Ng, M, Schonfeld, E.A, Pappas, A, Crismale, J, Stivala, A, Khaitova, V, Gardenier, D, Perumalswami, P, Schiano, T.D, Odin, J.A, Liu, L, Dieterich, D.T, Branch, A.D

Get full text

1137 EFFECTIVENESS OF HCV TRIPLE THERAPY WITH TELAPREVIR IN NEW YORK CITY by Martel-Laferriere, V, Bichoupan, K, Pappas, A, Schonfeld, E, Ng, M, Sefcik, R, Vachon, M.-L, Standen, M, Perumalswami, P, Schiano, T.D, Odin, J.A, Liu, L, Dieterich, D.T, Branch, A.D

Get full text

Factors Associated With Failure Of Telaprevir- And Boceprevir-Based Hcv Triple Therapy by Bichoupan, K, Tandon, N, Martel-Laferriere, V, Sachs, D, Ng, M, Schonfeld, E.A, Pappas, A, Crismale, J, Stivala, A, Khaitova, V, Gardenier, D, Linderman, M, Olson, W, Perumalswami, P, Schiano, T.D, Odin, J.A, Liu, L.U, Dieterich, D.T, Branch, A.D

Get full text

7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3 by Lawitz, E, Gane, E, Stedman, C, Lalezari, J.P, Hassanein, T, Kowdley, K.V, Poordad, F.F, Sheikh, A.M, Afdal, N.H, Bernstein, D.E, DeJesus, E, Freilich, B, Nelson, D.R, Dieterich, D.T, Jacobson, I.M, Jensen, D, Abrams, G.A, Darling, J.M, Rodriguez-Torres, M, Reddy, K.R, Sulkowski, M.S, Bzowej, N.H, DeMicco, M.P, Strohecker, J.S, Hyland, R.H, Anderson, J.K, Baker, C, Kirven, S, Hindes, R.G, Albanis, E, Symonds, W.T, Berrey, M.M

Get full text

[637] LIPID STEATOSIS, METABOLIC VARIABLES AND BODY COMPOSITION IN THE SETTING OF HIV/HCV COINFECTION; FINDINGS FROM A LARGE RANDOMIZED TRIAL by Rodriguez-Torres, M, Govindarajan, S, Sola, R, Clumeck, N, Lissen, E, Pessoa, M, Buggisch, P, Main, I, DePamphilis, J, Dieterich, D.T

Get full text

FRI-181 - A behavioral Intervention improves the rate of hepatitis C treatment initiation among HIV/HCV coinfected patients: results of a randomized controlled trial by Weiss, J.J., Aaronson, C., Cervantes, L., Georgi, M., Prochno, K., Miller, T.R., Kang, T., Prieto, S., Mhango, G., Heffron, S., Lugo, L.A., Fishberger, J., Zewde, M., Stivala, A., Douglas, O., Ferris, D., Dieterich, D.T., Wisnivesky, J.

Get full text

PIN3 - Factors Associated With Failure Of Telaprevir- And Boceprevir-Based Hcv Triple Therapy by Bichoupan, K., Tandon, N., Martel-Laferriere, V., Sachs, D., Ng, M., Schonfeld, E.A., Pappas, A., Crismale, J., Stivala, A., Khaitova, V., Gardenier, D., Linderman, M., Olson, W., Perumalswami, P., Schiano, T.D., Odin, J.A., Liu, L.U., Dieterich, D.T., Branch, A.D.

Get full text